Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Single Site, Open-label, Uncontrolled Study of FF-21101In / FF-21101Y in Patients with Solid Tumors that Relapsed or Metastasized after Standard Therapy

Next Previous
Trial Profile

A Phase 1, Single Site, Open-label, Uncontrolled Study of FF-21101In / FF-21101Y in Patients with Solid Tumors that Relapsed or Metastasized after Standard Therapy

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 23 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FF 21101 Y-90 (Primary)
  • Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer; Head and neck cancer; Ovarian cancer; Peritoneal cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors FUJIFILM Toyama Chemical

Most Recent Events

  • 25 Mar 2022 Status changed from recruiting to discontinued.
  • 28 Apr 2020 New trial record
  • 24 Apr 2020 According to a FUJIFILM Toyama Chemical media release, the company announced the initiation of this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top